Although the prevalent view used to be that tumor suppressors (which include metastasis suppressors) are un-targetable [141], there is now a paradigm shift since the recent report of Hsiue et al. [142] on p53 mutant peptide-targeted immunotherapy, albeit an antibody-based therapeutic that targets the most commonly mutated tumor suppressor gene. The gene discussed is TP53; the disease is neoplasm.